{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.8","upperLimit":"42.6","value":"31"},{"groupId":"OG001","lowerLimit":"23.9","upperLimit":"46.0","value":"34"},{"groupId":"OG002","lowerLimit":"25.5","upperLimit":"71.1","value":"48"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"99"},{"groupId":"OG002","value":"25"}],"units":"Participants"}],"description":"ORR was determined according to the 2016 international myeloma working group (IMWG) response criteria by IRC. ORR was calculated as the percentage of participants with a confirmed partial response (PR) or better (that is \\[i.e.\\], PR, very good partial response \\[VGPR\\], complete response \\[CR\\] and stringent complete response \\[sCR\\]). Confidence intervals were based on the exact method.","dispersionType":"97.5% Confidence Interval","groups":[{"description":"Participants were administered frozen liquid (30 mg/vial solution in a single use vial) at a dose of 2.5 mg/kg GSK2857916 as IV solution once every three weeks for a maximum of up to 39 cycles (1 cycle= 21 days). Frozen liquid was diluted with 0.9 percent saline.","id":"OG000","title":"Main Study: GSK2857916 2.5 mg/kg (Frozen Liquid)"},{"description":"Participants were administered frozen liquid (30 mg/vial solution in a single use vial) at a dose of 3.4 mg/kg GSK2857916 as IV solution once every three weeks for a maximum of up to 32 cycles (1 cycle= 21 days). Frozen liquid was diluted with 0.9 percent saline.","id":"OG001","title":"Main Study: GSK2857916 3.4 mg/kg (Frozen Liquid)"},{"description":"Participants were administered lyophilized powder (100 mg/vial in a single use vial) at a dose of 3.4 mg/kg GSK2857916 given IV for a maximum of 35 cycles (1 cycle= 21 days). Lyophilized powder was reconstituted using water for injection.","id":"OG002","title":"Main Study: GSK2857916 3.4 mg/kg (Lyophilized)"}],"paramType":"NUMBER","populationDescription":"Full Analysis Population comprised of all randomized participants (any participant who received a treatment randomization number was considered as randomized) whether or not randomized treatment was administered. This population was based on the treatment the participant was randomized to.","reportingStatus":"POSTED","timeFrame":"Up to 48 weeks","title":"Overall Response Rate (ORR) by Independent Review Committee (IRC) (Full Analysis Population)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}